Kidney

S0931

Description:

This Phase III study compares the recurrence-free survival as well as overall survival of patients with renal cell carcinoma receiving everolimus or placebo after full surgical resection and who have no residual or metastatic disease.


Type(s) of Cancer: Kidney
Study Phase(s): Phase III
Contact: Epp Goodwin at (210) 450-5798

SAHA+Hydroxychloroquine

Description:

SAHA is a HDAC inhibitor. SAHA may also block angiogenic signaling by inhibiting the VEGF receptors expression and also reduce circulating levels of inflammatory cytokines. In this study SAHA is administered with Hydroxychloroquine in patients with advanced solid tumors


Type(s) of Cancer: Kidney
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798